Literature DB >> 14987462

Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury.

Dunyue Lu1, Anton Goussev, Jieli Chen, Paul Pannu, Yi Li, Asim Mahmood, Michael Chopp.   

Abstract

Statins administered postischemia promote functional improvement in rats, independent of their capability to lower cholesterol. We therefore tested the effect of statin treatment on traumatic brain injury (TBI) in rats. Atorvastatin was orally administered (1 mg/kg/day) to Wistar rats starting 1 day after TBI for 7 consecutive days. Control animals received saline. Modified Neurological Severity Scores and Corner tests were utilized to evaluate functional response to treatment. Bromodeoxyuridine (BrdU, 100 mg/kg) was also intraperitoneally injected daily for 14 consecutive days to label the newly generated endothelial cells. Rats were sacrificed at day 14 after TBI, and the brain samples were processed for immunohistochemical staining. Atorvastatin administration after brain injury significantly reduced the neurological functional deficits, increased neuronal survival and synaptogenesis in the boundary zone of the lesion and in the CA3 regions of the hippocampus, and induced angiogenesis in these regions. The results suggest that atorvastatin may provide beneficial effects in experimental TBI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14987462     DOI: 10.1089/089771504772695913

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  73 in total

1.  The treatment of traumatic brain injury with velcade.

Authors:  Changsheng Qu; Asim Mahmood; Ruizhuo Ning; Ye Xiong; Li Zhang; Jieli Chen; Hao Jiang; Michael Chopp
Journal:  J Neurotrauma       Date:  2010-09       Impact factor: 5.269

2.  Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: magnetic resonance imaging and histological study.

Authors:  Dongmei Yang; Robert A Knight; Yuxia Han; Kishor Karki; Jianfeng Zhang; Christopher Ding; Michael Chopp; Donald M Seyfried
Journal:  J Neurosurg       Date:  2010-08-20       Impact factor: 5.115

Review 3.  Investigational agents for treatment of traumatic brain injury.

Authors:  Ye Xiong; Yanlu Zhang; Asim Mahmood; Michael Chopp
Journal:  Expert Opin Investig Drugs       Date:  2015-03-01       Impact factor: 6.206

Review 4.  Angiogenesis, neurogenesis and brain recovery of function following injury.

Authors:  Ye Xiong; Asim Mahmood; Michael Chopp
Journal:  Curr Opin Investig Drugs       Date:  2010-03

Review 5.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

6.  Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice.

Authors:  Ye Xiong; Asim Mahmood; Dunyue Lu; Changsheng Qu; Anton Goussev; Timothy Schallert; Michael Chopp
Journal:  Brain Res       Date:  2007-10-31       Impact factor: 3.252

7.  Statins in acute brain injury: getting the cart before the horse.

Authors:  Daniel T Laskowitz; David S Warner
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 8.  Animal models of traumatic brain injury.

Authors:  Ye Xiong; Asim Mahmood; Michael Chopp
Journal:  Nat Rev Neurosci       Date:  2013-02       Impact factor: 34.870

9.  Long-lasting benefits after treatment of traumatic brain injury (TBI) in rats with combination therapy of marrow stromal cells (MSCs) and simvastatin.

Authors:  Asim Mahmood; Anton Goussev; Dunyue Lu; Changsheng Qu; Ye Xiong; Humaira Kazmi; Michael Chopp
Journal:  J Neurotrauma       Date:  2008-12       Impact factor: 5.269

Review 10.  Mechanisms of radiation-induced brain toxicity and implications for future clinical trials.

Authors:  Jae Ho Kim; Stephen L Brown; Kenneth A Jenrow; Samuel Ryu
Journal:  J Neurooncol       Date:  2008-01-22       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.